For six years, Americans who needed Amitiza, a prescription drug for chronic constipation, had no cheaper option. A generic version existed, practically speaking. The only reason it wasn't on shelves was that the company making the brand-name drug had paid its would-be competitor to stay away.

A federal jury in Boston ruled on Monday that this arrangement, made by Japan's Takeda Pharmaceutical, violated U.S. antitrust law. The verdict set damages at roughly $885 million. Because antitrust law allows damages to be tripled, the final bill could climb into the several-billion-dollar range.

The scheme, explained

The pharmaceutical industry has a long-running playbook for keeping generics off the market. A brand-name drugmaker gets sued by a generic competitor challenging its patents. Rather than fight the case in court and risk losing (which would immediately open the market to cheaper drugs), the brand-name company settles. The settlement includes money, or a sweetheart partnership deal, that makes it worth the generic company's while to wait.

These arrangements are called "pay-for-delay" deals. The U.S. Supreme Court ruled in 2013 that they can violate antitrust law, and a wave of lawsuits has followed. Monday's verdict is the first time a jury has actually found a drug company liable in class-action litigation over one. Three earlier trials ended with wins for the defendants.

In this case, Takeda and its partner Sucampo Pharmaceuticals sued Par Pharmaceutical in 2012 when Par sought approval for a generic version of Amitiza. They settled in 2014. Par agreed to hold off until January 2021, when it was then allowed to sell an authorized version of the drug supplied by Sucampo under a profit-sharing arrangement. Lawyers for the plaintiffs called this a $210 million payoff that delayed real generic competition by six years. Takeda's lawyers argued the settlement was lawful and actually increased competition by resolving patent uncertainty.

The jury sided with the plaintiffs.

Who pays, and who got paid

The people who brought this case were not individual patients. They were the middlemen of the drug economy: pharmacies including CVS and Walgreens, insurers, health funds, and wholesalers. The jury awarded CVS $191 million and Walgreens $121 million, along with $474.9 million to direct purchasers like pharmacies and wholesalers, and $63.2 million to insurers and other end-payers.

Those institutions overpaying for a drug is not an abstract corporate complaint. It feeds directly into what insurers charge in premiums and what pharmacy benefit programs pay out. The cost ultimately lands somewhere, and that somewhere is usually the person with the prescription.

Takeda denied wrongdoing throughout the trial and said it will appeal vigorously. The company's shares actually rose 0.6% on Tuesday morning, possibly because investors had priced in worse outcomes or because the appeal timeline is long. Takeda said it does not expect its current financial forecasts to be materially affected, aside from its free cash flow, depending on when and whether any payment is made.

The bigger pattern

This verdict matters beyond Amitiza. Brand-name drug companies have used pay-for-delay settlements for decades because the economics made sense: paying a competitor to wait was cheaper than losing a patent case and watching your market share evaporate overnight. The 2013 Supreme Court ruling opened the door to legal challenges, but actually winning at trial has proven hard. Until now.

A first jury win changes the calculus. It signals that these cases can succeed with juries, which makes future settlements by drug companies more expensive and future pay-for-delay deals riskier to structure. That won't fix drug pricing broadly, but it applies pressure to one of the more cynical corners of the system.

Generic drugs typically cost 80 to 85 percent less than their brand-name equivalents once they reach the market. Every year that entry is delayed is a year that savings never arrive.